DGAP-News

MOLOGEN to present poster at European Cancer Congress 2015 (news with additional features)

DGAP-News: MOLOGEN AG / Key word(s): Conference
MOLOGEN to present poster at European Cancer Congress 2015 (news with
additional features)

24.09.2015 / 09:10

---------------------------------------------------------------------

PRESS RELEASE N 16 / 2015 of 09/24/2015

MOLOGEN to present poster at European Cancer Congress 2015

Berlin, September 24, 2015 - The biotechnology company MOLOGEN AG will
present a poster on the immunotherapy MGN1703 at the European Cancer
Congress (ECC 2015) in Vienna (September 25 - 29, 2015). The poster is
featuring data from the phase II IMPACT trial in colorectal cancer
patients. Furthermore, in the framework of the conference, an investigator
meeting is scheduled for the randomized lung cancer study IMPULSE.

Abstract details:
Abstract number: 2089 (used in the programme and online abstract book)
Title: "Response to chemotherapy allows to identify mCRC patients most
likely to benefit from maintenance immunotherapy: A post-hoc analysis from
the IMPACT study"
Poster presentation: "Gastrointestinal Malignancies - Colorectal Cancer" on
September 27, 2015 from 9:15 a.m. to 11:15 a.m. in Hall C.

For more information on the ECC 2015 please visit the website
www.europeancancercongress.org .

MOLOGEN AG
With new and unique technologies and active substances, the biotech company
MOLOGEN is one of the pioneers in the field of immunotherapy. Alongside a
focus on immuno-oncology, MOLOGEN also develops immunotherapies for the
treatment of infectious diseases.

The cancer immunotherapy MGN1703 is the company's lead product and
best-in-class TLR9 agonist. Treatment with MGN1703 triggers a broad and
strong activation of the immune system. Due to this mechanism of action,
MGN1703 has the potential to be applied to various indications. MGN1703 is
currently being developed for first-line maintenance treatment of
colorectal cancer (pivotal study) and small cell lung cancer (randomized
controlled trial). Furthermore it is also being investigated in a phase I
study in HIV.
MOLOGEN's pipeline focus is on new innovative immunotherapies to treat
diseases for which there is a high medical need.

MOLOGEN AG is listed on the stock exchange and its headquarters are located
in Berlin, Germany. The shares of the company are listed on the Prime
Standard at the Frankfurt Stock Exchange (ISIN DE0006637200).

www.mologen.com

Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V.
| DECHEMA - Society for chemical technology and biotechnology e.V. |